Parathyroid cancer secondary prevention

	Parathyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Parathyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Parathyroid cancer secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Parathyroid cancer secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Parathyroid cancer secondary prevention
CDC on Parathyroid cancer secondary prevention
Parathyroid cancer secondary prevention in the news
Blogs on Parathyroid cancer secondary prevention
Directions to Hospitals Treating Type chapter name here
Risk calculators and risk factors for Parathyroid cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.